We are a group of privately held biotech companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases.
Acquired by Millendo Therapeutics in December 2017
Acquired by Jazz Pharmaceuticals (Nasdaq: JAZZ) in March 2016
Program: I-HBD1, peptide with bone anabolic properties for the treatment of rare bone diseases and osteoporosis
Status: Lead optimization